PROGRAM - Tuesday, June 5, 2012
 
PROGRAM - TUESDAY, JUNE 5, 2012
7:30AM-8:30AM
EDUCATIONAL SYMPOSIUM
MAXIMIZING ONCOLOGY ACCESS: TRENDS AND EVOLVING EVIDENCE REQUIREMENTS (Sponsored by Xcenda) View Symposium Description »
8:45AM-1:15PM
8:45AM-9:45AM
RESEARCH PODIUM PRESENTATIONS – SESSION III
 

HEALTH CARE POLICIES & EXPENDITURES

8:45AM-9:00AM

HC1

DID MASSACHUSETTS HEALTH REFORM LOWER HOSPITAL INPATIENT COST?

 

Wong H, Karaca Z
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

9:00AM-9:15AM

HC2

ASSOCIATION OF ALLERGIC RHINITIS WITH ASTHMA EXACERBATIONS AND HEALTHCARE COSTS IN ASTHMA PATIENTS

 

Ivanova JI1, Desai U2, Birnbaum HG2, Cummings AK2, Bornstein A2, Karafilidis J3, Spalding W4
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA, 4Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA

9:15AM-9:30AM

HC3

ASSESSING THE VALUE OF BIOPHARMACEUTICALS: COST-EFFECTIVE INNOVATIONS OR INEFFICIENT USE OF RESOURCES?

 

Wilson A1, Neumann PJ2
1Brandeis University, Waltham, MA, USA, 2Tufts Medical Center, Boston, MA, USA

9:30AM-9:45AM

HC4

CMS'S USE OF COST-EFFECTIVENESS EVIDENCE IN NCDS FOR PREVENTION

 

Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA

  INFECTIOUS DISEASE OUTCOMES RESEARCHH
8:45AM-9:00AM

IN1

ANTIBIOTIC PRESCRIBING VIA TELEPHONE: HOW OFTEN DOES IT OCCUR?

 

Willey VJ1, Ewen E2, Vichaichanakul K1, Khole T1, Dabeer P1, Loka N1, McGhan WF1, Drees M2
1University of the Sciences, Philadelphia, Philadelphia, PA, USA, 2Christiana Care, Newark, DE, USA

9:00AM-9:15AM

IN2

COMPARATIVE EFFICACY AT 48 WEEKS OF ATAZANAVIR/RITONAVIR VERSUS DARUNAVIR/RITONAVIR IN TREATMENT NAIVE HIV-1 PATIENTS: A MATCHING ADJUSTED INDIRECT COMPARISON OF RANDOMIZED TRIALS

 

Xie J1, Juday T2, Swallow E1, Du X1, Uy J2, Hebden T2, Signorovitch J1
1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA

9:15AM-9:30AM

IN3

TRANSLATING OUTCOMES FROM A DYNAMIC TRANSMISSION MODEL FOR VARICELLA VACCINATION TO COST-EFFECTIVENESS ESTIMATES: THE IMPACT OF DIFFERENT ANALYTIC APPROACHES ON THE RESULTS

 

Thompson JR1, Talbird SE1, Mauskopf JA1, Brogan A1, Standaert B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline Biologicals, Wavre, Belgium

9:30AM-9:45AM

IN4

HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS TREATED FOR NOSOCOMIAL PNEUMONIA (NP) CAUSED BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): SECONDARY ANALYSIS OF A MULTI-CENTER RANDOMIZED CONTROLLED STUDY

 

Solem CT1, Niederman MS2, Chastre J3, Wan Y1, Gao X1, Myers DE4, Haider S5, Chambers R4, Li JZ6, Van Hout BA7, Stephens JM1
1Pharmerit International, Bethesda, MD, USA, 2Winthrop-University Hospital, Mineola, NY, USA, 3Institut de Cardiologie, Paris, France, 4Pfizer, Inc., Collegeville, PA, USA, 5Pfizer, Inc., Groton, CT, USA, 6Pfizer, Inc., San Diego, CA, USA, 7University of Sheffield, Sheffield, UK

  HEALTH-RELATED PRODUCTIVITY
8:45AM-9:00AM

PR1

FDA ACTIONS AGAINST HEALTH ECONOMIC PROMOTIONS, 2002-2011

 

Neumann PJ, Bliss S
Tufts Medical Center, Boston, MA, USA

9:00AM-9:15AM

PR2

THE IMPACT OF MINIMALLY INVASIVE SURGICAL TECHNOLOGY ON THE COSTS OF EMPLOYEE ABSENTEEISM

 

Epstein AJ, Groeneveld PW, Harhay M, Yang F, Polsky D
University of Pennsylvania, Philadelphia, PA, USA

9:15AM-9:30AM

PR3

QUALITATIVE ASSESSMENT OF HEALTH-RELATED PRODUCTIVITY INSTRUMENTS

 

Tundia NL1, Heaton PC1, Kelton CM2, Hass S3, Fuldeore M3
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business, Cincinnati, OH, USA, 3Abbott Laboratories, Abbott Park, IL, USA

9:30AM-9:45AM

PR4

BREAST CANCER MORTALITY RATES BY GEOGRAPHIC REGION, YEARS OF POTENTIAL LIFE LOST, AND VALUE OF PRODUCTIVITY LOSSES AMONG WOMEN AGED 20-49 YEARS IN THE UNITED STATES, 1970–2008

 

Ekwueme DU, Guy GP, Rim SH, Hall IJ, Thomas CC, Fairley TL, Rodriguez J, White A
Centers for Disease Control and Prevention, Atlanta, GA, USA

  RESEARCH ON MEDICAL OUTCOMES QUESTIONNAIRES
8:45AM-9:00AM

QU1

THE DEVELOPMENT AND VALIDATION OF A REVISED VERSION OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE (MOS-SLEEP-R)

 

Yarlas AS, White MK, Smith KJ, Bjorner JB
QualityMetric Incorporated, Lincoln, RI, USA

9:00AM-9:15AM

QU2

CROSS-CULTURAL PSYCHOMETRIC EVALUATION OF THE ENSEMBLE MDS

 

Bushnell DM1, McCarrier KP2, Martin ML2, Paczkowski R3, Shen W3, Buesching D3
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Eli Lilly and Company, Inc., Indianapolis, IN, USA

9:15AM-9:30AM

QU3

PSYCHOMETRICS OF THE ACTINIC KERATOSIS RISK QUESTIONNAIRE: A RISK ASSESSMENT INSTRUMENT

 

Balkrishnan R1, Kulkarni AS2, Gatwood J1, Anderson RT3, Narahari S4, Landis E4, Feldman SR4
1University of Michigan, Ann Arbor, MI, USA, 2Leo Pharma, Parsippany, NJ, USA, 3Pennsylvania State University, Hershey, PA, USA, 4Wake Forest University School of Medicine, Winston-Salem, NC, USA

9:30AM-9:45AM

QU4

ASSESSING THE VALIDITY AND RELIABILITY OF A PATIENT SATISFACTION SURVEY FOR AN EMPLOYER-SPONSORED MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

 

Majercak K, Pinto S, Bechtol R, Borse M
The University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA

  DRUG UTILIZATION & PRICING
8:45AM-9:00AM

UT1

THE IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON DRUG UTILIZATION IN THE UNITED STATES

 

Doyle JJ, Sepulveda B
Quintiles Global Consulting, Hawthorne, NY, USA

9:00AM-9:15AM

UT2

IMPACT OF 2009-2011 GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH OUTCOMES STRATEGY

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

9:15AM-9:30AM

UT3

FIRM- AND DRUG-SPECIFIC PATTERNS OF GENERIC DRUG PRICES EXPERIENCED BY UNITED STATES MEDICAID PROGRAMS: 1991-2008

 

Berry EA1, Kelton CM2, Yu Y2, Guo JJ3, Bian B1, Heaton PC1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business, Cincinnati, OH, USA, 3University of Cincinnati Medical Center, Cincinnati, OH, USA

9:30AM-9:45AM

UT4

PHARMACEUTICAL PRICING BASED ON EARLY BENEFIT ASSESSMENTS

 

Gissel C
Justus Liebig University Giessen, Giessen, Hessen, Germany

9:45AM-10:00AM
10:00AM-11:00AM
ISSUE PANELS – SESSION II
10:00AM-11:00AM CLINICAL OUTCOMES RESEARCH ISSUES
IP6: ONCOLOGY COMPARATIVE EFFECTIVENESS RESEARCH: WHAT IS IT AND WHAT MAKES IT USEFUL?

Moderator: Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA
Panelists:
Sean D. Sullivan, PhD, RPh, MS, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA; Art Small, MD, Head, Oncology Outcomes Research, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA; Jennifer Malin, MD, PhD, Medical Director Oncology, WellPoint, Inc., Thousand Oaks, CA, USA
10:00AM-11:00AM ECONOMIC OUTCOMES RESEARCH ISSUES
IP7: DO DECISION MAKERS REALLY USE BUDGET IMPACT MODELS GENERATED BY PHARMACEUTICAL MANUFACTURERS?

Moderator: Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA
Panelists: John Graham, PharmD, Group Director, Health Services, Bristol-Myers Squibb Company, Plainsboro, NJ, USA; Richard Lieblich, RPh, Vice President, Industry Relations, MedImpact Healthcare Systems, Inc, San Diego, CA, USA; John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA
10:00AM-11:00AM HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP8: ACCELERATING THE DEVELOPMENT OF COMPARATIVE EFFECTIVENESS INFORMATION: DOES PHASE 3B REPRESENT AN OPPORTUNITY?

Moderator: Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA
Panelists: Sean R. Tunis, MD, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA; Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency, London, UK; Robert Temple, MD, Director of the Office of Medical Policy, U.S. Food and Drug Administration, Silver Spring, MD, USA
10:00AM-11:00AM IP9: OUTSIDER PERSPECTIVES ON THE UNITED STATES COMPARATIVE EFFECTIVENESS RESEARCH MOVEMENT: REAL PROGRESS OR REAL DISAPPOINTMENT?
Moderator: David Thompson, PhD, Senior Vice President, Life Sciences, OptumInsight, Medford, MA, USA
Panelists: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Federico Augustovski, MD, MSc, Director, Health Economic Evaluation and Technology Assessment Department, Hospital Italiano de Buenos Aires, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria
10:00AM-11:00AM PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH (PCOR): CAN WE MAKE IT MEANINGFUL?

Moderator: Patricia A. Deverka, MD, MS, Senior Research Director, Center for Medical Technology Policy, Baltimore, MD, USA
Panelists: Jessie Gruman, PhD, President, Center for Advancing Health, Washington, DC, USA; Eleanor Perfetto, MS, PhD, Senior Director, Pfizer, Inc., Washington, DC, USA; Melissa McPheeters, MPH, PhD, Research Associate Professor & Co-Director, Vanderbilt Evidence-based Practice Center, Co-Director, Emphasis Program Area on Healthcare and Public Health Research and Management, Deputy Director, Women’s Health Research, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA
11:00AM-1:15PM
11:15AM-12:15PM
EDUCATIONAL SYMPOSIUM
PHARMACOECONOMIC MODELING: THE ROAD TO PRIMETIME (Sponsored by Archimedes) View Symposium Description »
12:15PM-1:15PM
1:15PM-3:30PM
RESEARCH POSTER PRESENTATIONS HALL CLOSED
1:15PM-2:00PM
WELCOME AND ISPOR SCIENTIFIC AND SERVICE AWARDS PRESENTATIONS
Mark J. Sculpher MSc, PhD Mark J. Sculpher MSc, PhD
2011-2012 ISPOR President and Professor of Health Economics, Centre of Health Economics, University of York, Heslington, York, UK
2012 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARD Presented by: Michael Drummond, PhD, University of York, Heslington, York, UK, and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Value in Health Co-Editors-in-Chief
Nicola J. Cooper, PhDAWARDEE: Nicola J. Cooper, PhD, Department of Health Sciences, University of Leicester, Leicester, UK

For the paper, “How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health Care Evaluation?” Value Health 2011;14:371-390.

2012 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD Presented by: Rajesh Balkrishnan, PhD, Chair, ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research Committee and Associate Professor, Department of Clinical, Social and Administrative Sciences, University of Michigan, Ann Arbor, MI, USA
Susan C. GriffinAWARDEE: Susan C. Griffin, Centre for Health Economics, University of York, Heslington, York, UK

For the paper, “Dangerous Omissions: The Consequences Of Ignoring Decision Uncertainty” Health Econ 2011;20:212–24.

2012 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD Presented by: Anirban Basu, PhD, Chair, ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Committee and Associate Professor, Dept. of Health Services, School of Public Health, University of Washington, Seattle, WA, USA
Niteesh K. Choudhry, MD, PhDAWARDEE: Niteesh K. Choudhry, MD, PhD, Associate Professor, Harvard Medical School, Boston, MA, USA

For the paper, “Full Coverage for Preventive Medications after Myocardial Infarction” N Engl J Med 2011;365:2088-97.

2012 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD Presented by: Shelby Reed, PhD, RPh, Chair, ISPOR Bernie J. O’Brien New Investigator Award Committee, Professor and Assistant Research Professor, Duke Clinical Research Institute, Durham, NC, USA

Joanne LaFleur, PharmD, MSPHAWARDEE: Joanne LaFleur, PharmD, MSPH, Assistant Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA

ISPOR SERVICE AND DISTINGUISHED SERVICE AWARDS Presented by: Mark J. Sculpher, MSc, PhD, 2011-2012 ISPOR President, Professor of Health Economics Centre for Health Economics, University of York, Heslington, York, UK

ISPOR Board of Directors Service Awards

ISPOR Distingished Service Awards

ISPOR STUDENT AWARDS
Presented by: Zeba M. Khan, PhD, RPh, ISPOR Student Network Advisor & VP, Pricing & Market Access, Celgene Corporation, Summit, NJ, USA

PhRMA FOUNDATION 2012 AWARDS IN HEALTH OUTCOMES Presented by: Eileen Cannon, Executive Director, PhRMA, Foundation, Washington, DC, USA
2:00PM-2:15PM
INCOMING PRESIDENTIAL ADDRESS
 

Deborah Marshall, PhD, MHSADeborah Marshall, PhD, MHSA
2011-2012 ISPOR President-Elect, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

2:15PM-3:30PM
SECOND PLENARY SESSION
  SECOND PLENARY SESSION: HEALTH REFORM IN THE US: BETTER HEALTH, BETTER CARE, LOWER COST
The US Patient Protection and Affordable Care Act (ACA), a major health care reform legislation enacted March 2010, contained 10 titles for  better health and health care at lower cost for all US citizens. Some provisions of the Act were effective immediately and other provisions effective 2010 to 2020. Provisions of the Act included: a requirement for individuals not covered by health insurance to maintain a minimal essential health insurance coverage; reform in the health insurance industry - community rating so applicants with the same age/location are offered the same premium; increased insurance coverage of pre-existing conditions; expanded Medicaid eligibility; health insurance exchanges offering a marketplace for citizens and small businesses to openly compare policies and premiums; no co-pays or deductibles on an “essential benefits package”; and more.

The US health care system will be briefly presented, followed by an in-depth discussion of the titles of the Act, including what provisions of the Act have been implemented; what is going right; what is going wrong; and the financial implications of the Act. The discussion will be followed with a review of State level initiatives which aim to achieve better health and better care at lower cost. The State of Maryland which has introduced several innovative health care reform programs will be used as an example.

Susan Dentzer, MA Moderator/Speaker:
Susan Dentzer, MA, Editor-in-Chief, Health Affairs, Bethesda, MD, USA
John E. McDonough, DrPH, MPA Speakers:
John E. McDonough, DrPH, MPA, Professor of the Practice of Public Health, Director of the Center for Public Health Leadership, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
Joshua M. Sharfstein, MD Joshua M. Sharfstein, MD, Secretary, Maryland Department of Health and Mental Hygiene, Baltimore, MD, USA
3:30PM-4:00PM
BREAK & EXHIBITS VIEWING
3:45PM-7:45PM
4:00PM-5:00PM
WORKSHOPS – SESSION II
4:00PM-5:00PM CLINICAL OUTCOMES RESEARCH
W8: INTRODUCTION TO USE OF INFORMATIVE VARIANCE PRIORS AND ADVANCED HETEROGENEITY MODELLING ISSUES IN RANDOM-EFFECTS MULTIPLE TREATMENT COMPARISON META-ANALYSIS

Discussion Leaders: Kristain Thorlund, PhD, Assistant Professor, McMaster University, Hamilton, ON, Canada; Edward Mills, PhD, MSc, Associate Professor, University of Ottawa, Ottawa, ON, Canada; Neil Hawkins, PhD, Director, Oxford Outcomes Ltd., Oxford, UK
4:00PM-5:00PM ECONOMIC OUTCOMES RESEARCH
W9: USING ECONOMIC THEORY TO GUIDE THE SPECIFICATION OF HEALTH CARE UTILIZATION AND EXPENDITURE MODELS

Discussion Leaders: William Crown, PhD, President, OptumInsight, Waltham, MA, USA; Richard J. Willke, PhD, Senior Director & Group Lead, Global Health Economics & Outcomes Research, Pfizer, Inc., New York, NY, USA
4:00PM-5:00PM HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W10: DISTANT CRIES: CUSTOMISING TRIAL DESIGN AND EVIDENCE SUBMISSION IN AN EMERGING MARKETS INTENSIVE WORLD

Discussion Leaders: Cyrus A. Chowdhury, MSc, Practice Leader, Global Market Access, Insight Strategy Advisors, New York, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow, European Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK, UK; Monica Martin de Bustamante, AB, Principal, Global Market Access, Insight Strategy Advisors, Geneva, Switzerland; Rachel Beckerman, PhD, Principal, Global Market Access, Insight Strategy Advisors, Geneva, Switzerland
4:00PM-5:00PM W11: DEVELOPING GUIDANCE FROM HTA AND COVERAGE BODIES TO INFORM CLINICAL TRIAL DESIGN: THE GREEN PARK COLLABORATIVE
Discussion Leaders: Sean R. Tunis, MD, MSc, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA; Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA; Newell McElwee, PharmD, Executive Director, US Outcomes Research, Merck & Co, Inc., New York, NY, USA
4:00PM-5:00PM W12: ADAPTING TO EVOLVING GLOBAL EVIDENCE REQUIREMENTS IN MEDICAL DEVICE DEVELOPMENT PROGRAMS
Discussion Leaders: Thomas Goss, PharmD, Vice President, Boston Healthcare Associates, Inc., Boston, MA, USA; Sheri Dodd, MSc, Vice President, Reimbursement, Economics and Health Policy, Cardiac Rhythm Disease Management, Medtronic Inc., Mounds View, MN, USA; Liesl Cooper, PhD, Vice President, Global Healthcare Economics, Policy & Reimbursement, Covidien, Mansfield, MA, USA; Bernd Brueggenjuergen, MD, MPH, Managing Director, Boston Healthcare GmbH, Celle, Germany
4:00PM-5:00PM HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
W13: EXPERIENCES IN THE APPLICATION OF BEST-WORST SCALING METHODS

Discussion Leaders: Christine Poulos, PhD, Senior Economist, Health Preference Assessment, RTI International, Research Triangle Park, NC, USA; John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Emily Lancsar, PhD, Associate Professor, Centre for Health Economics, Monash University, Clayton, Victoria, Australia
4:00PM-5:00PM USE OF REAL WORLD DATA
W14: REAL WORLD EVIDENCE: FEASIBILITY AND ADVANTAGES OF LINKING PAYER AND PRACTITIONER DATA FOR RESEARCH

Discussion Leaders: Chakkarin Burudpakdee, PharmD, Director, Health Economics and Outcomes Research, IMS Health Consulting Group, Alexandria, VA, USA; Jerrold Hill, PhD, Engagement Manager, HEOR, IMS Health, Plymouth Meeting, PA, USA; Dennis Raisch, PhD, RPh, MS, Professor & Chair, PEPPOR Graduate Program, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
5:15PM-6:15PM
ISPOR FORUMS – SESSION II
5:15PM-6:15PM ASSESSING RETROSPECTIVE OBSERVATIONAL STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing retrospective observational studies for health care decision makers will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI). The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Interpreting Retrospective Observational Studies for Health Care Decision Makers Task Force

Moderator & Speaker: Bradley Martin, PhD, RPh, PharmD, Chair, CER-CI Interpreting Retrospective Observational Studies for Health Care Decisions Task Force and Professor & Division Chair, College of Pharmacy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Speaker: William Crown, PhD, President, Innovus, Waltham, MA, USA

5:15PM-6:15PM ASSESSING THE BODY OF EVIDENCE ACROSS MULTIPLE STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing the body of evidence across multiple studies for health care decision makers as one of the work products developed by Part 2 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI) will be presented during this forum. The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Synthesizing a Body of Evidence Task Force

Moderators & Speakers: Helen Sherman, PharmD, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Chief Pharmacy Officer of Pharmacy Services, RegenceRx, Portland, OR, USA; Brian Sweet, MBA, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Executive Director Development, Managed Markets, AstraZeneca Pharmaceuticals, L.P., Wilmington, DE, USA

5:15PM-6:15PM ISPOR GOOD RESEARCH PRACTICES FOR THE ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN CHILDREN AND ADOLESCENTS
This forum will focus on best practices for PRO research with children and adolescents in the regulatory context to support claims in medical product labeling. Methodological challenges, including developmental differences, age-based cutoffs, appropriate instrument design/formatting, and approaches for establishing content validity will be discussed. Presented by the Patient-Reported Outcomes Assessment in Children and Adolescents Task Force

Moderator & Speaker: Louis Matza, PhD, Chair, ISPOR Pediatric and Adolescent PRO Task Force andResearch Scientist, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA

Speakers: John J. Alexander, MD, MPH, Medical Team Leader, Division of Anti-Infective and Ophthalmology Products, US Food and Drug Administration (FDA), Silver Spring, MD, USA; Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services and Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA; Anne W. Riley, PhD, MS, Professor, Department of Population, Family & Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
5:15PM-6:15PM DESIGNING CONJOINT EXPERIMENTS: A GUIDE TO ALTERNATIVE STRATEGIES
The task force will discuss application of experimental-design approaches for discrete-choice experiments in health and health care.  Topics include model identification, statistical versus response efficiency, and particular challenges in developing experimental designs for health studies.  A summary and comparison of six practical experimental-design approaches will be provided. Presented by the ISPOR Conjoint Analysis Experimental Design Task Force

Moderator: John F. P. Bridges, PhD, Associate Professor, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Speakers: Emily Lancsar, PhD, Associate Professor, Centre for Health Economics, Faculty of Business and Economics, Monash University, Melbourne, Victoria, Australia; F. Reed Johnson, PhD, Chair, ISPOR Conjoint Analysis Experimental Design Task Force, Distinguished Fellow and Principal Economist, Health Preference Assessment Group, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA; Axel Muehlbacher, PhD, Professor, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

5:15PM-6:15PM ISPOR VISION 2020: A LOOK TO THE FUTURE
During this forum, the ISPOR Vision 2020 Implementation Task Force Working Group Chairs will present the results of the ISPOR Vision 2020 Survey as well as Vision 2020 Implementation Task Force activities and recommended actions.  Attendees will have an opportunity to respond to recommended actions. Presented by the ISPOR Vision 2020 Implementation Task Force.

Moderator: Mark J. Sculpher, MSc, PhD, ISPOR Vision 2020 Implementation Task Force Chair & Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Speakers: Ansgar Hebborn, PhD, ISPOR Vision 2020 Implementation Task Force Research Working Group Chair & Head - Global Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland; Sean D. Sullivan, PhD, RPh, MS, ISPOR Vision 2020 Implementation Task Force Education Working Group Chair and Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA; Shelby Reed, PhD, RPh, ISPOR Vision 2020 Implementation Task Force Communications Working Group Chair and Associate Professor, Duke Clinical Research Institute, Durham, NC, USA

5:15PM-6:15PM INTERNATIONAL PERSPECTIVES ON CHANGING EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES AND DIAGNOSTICS: ADDRESSING THE MOVING TARGET PROBLEM FOR MEDICAL TECHNOLOGIES
Global policies and expectations related to medical device and diagnostic technologies are evolving rapidly. This forum will provide detailed insights from US, Europe, and Japan on recent policy and procedural changes in evidentiary requirements.  Emerging options for aligning value demonstration with decision maker needs will be discussed. Presented by the ISPOR HTA Special Interest Group

Moderator: Annie Chicoye, PhD, Chair, ISPOR HTA of Medical Devices & Diagnostics Working Group and Executive Director for Development, Health Management Institute, ESSEC Business School Paris-Singapore, Cergy Pontoise Cedex, France

Speakers: Susan Garfield, PhD, Vice President, Bridgehead International, Wayland, MA, USA; Eric Faulkner, MPH, Director, Global Market Access, Quintiles and Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA; Sophie Cros, PharmD, MBA, Director, Regulatory Affairs, Reimbursement and Health Economics, EMA, Abbott Vascular International BVBA, Diegem, Belgium; Ataru Igarashi, PhD, Assistant Professor, Department of Drug Policy and Management Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

5:15PM-6:15PM PROBLEMS, PITFALLS, AND PRAGMATICS OF PHARMACOECONOMICS: LESSONS FROM THE AFRICAN EXPERIENCE
The use of pharmacoeconomics in health services on the African continent is limited; this, however, is not due to the lack of need but due to limited resources. The need is emphasized by the lack of access to health care on the African continent. Egypt is currently establishing a pharmacoeconomics unit within the Ministry of Health and is focusing on issues related to pricing and reimbursement process. Ghana has received training from the WHO on pharmacoeconomics and is looking into establishing a pharmacoeconomics unit within the Ministry of Health. Nigeria is taking steps to start promoting pharmacoeconomics in the country. South Africa has pharmacoeconomic guidelines within the government sector while HTA is an accreditation requirement in the private sector. This forum will provide an in-depth review of African attitudes toward pharmacoeconomics, knowledge of drug costs, awareness and perceived uses of pharmacoeconomic literature, views on perceived barriers to pharmacoeconomic implementation and how those needs and barriers should be addressed.  Speakers will provide knowledge and understanding of current principles and practices on pharmacoeconomics, relevant to the African countries. Presented by the ISPOR Egypt, Ghana, Nigeria and South Africa Regional Chapters

Moderator: Emmanuel Ankrah Odame, MBChB, MPH, Health Policy Analyst, Ghana College of Physicians and Surgeons, Accra, Ghana

Speakers: Mohammed Hassan Solayman, MSc, Assistant Lecturer, Faculty of Pharmacy, Clinical Pharmacy Department, Ain Shams University, Cairo, Egypt; Martha Gyansa-Lutterodt, MA, MSc, Director of Pharmaceutical Services and Chief Pharmacist, Ghana Ministry of Health, Accra, Ghana; Anthony Waka Udezi, MPharm, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Benin, Benin City, Nigeria; Jacques Snyman, MBChB, MPharmMed, MD, President, ISPOR South Africa Regional Chapter and Director, Product Development, Agility Global Health Solutions, Pretoria, South Africa

6:15PM-7:15PM
6:15PM-7:45PM
8:00PM-11:30PM
ISPOR SOCIAL EVENT - Live music, dinner and dancing at the Front Page Restaurant on Dupont Circle!
 





Scott D. Ramsey MD, PhD

Dr. Ramsey is general internist and health economist. He is a Member in the Cancer Prevention Program, Division of Public Health Science at the Fred Hutchinson Cancer Research Center. He directs the Cancer Technology Assessment Group, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the School of Medicine, School of Pharmacy, and the Institute for Public Health Genetics at the University of Washington. He also directs the Cancer Prevention and Survivorship Program at the Seattle Cancer Care Alliance.

Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His current studies—funded by the National Cancer Institute, National Human Genome Research Institute, Centers for Disease Control and Prevention, and several pharmaceutical manufacturers—include projects to develop a genetic screening policy model for colorectal cancer, a multicenter study of decision making for men with newly diagnosed prostate cancer, and studies of cancer screening, incidence, treatment, and outcomes for Native Americans diagnosed with cancer. Along with investigators at the University of Washington, Dr. Ramsey co-directs an NCI-funded training program in Biobehavioral and Cancer Outcomes Research. He is a member of the Institute of Medicine’s National Cancer Policy Forum.

Dr. Ramsey has served ISPOR in several capacities: as Chair, Task Force on Cost-Effectiveness Analysis alongside Clinical Trials; Director, 2005-2007 ISPOR Board of Directors; Chair, 12th Annual International Meeting, and Chair and current member, Value in Health Management Advisory Board.


Nicola J. Cooper, PhD

Nicola J. Cooper, PhD, is a Professor of Healthcare Evaluation Research at the University of Leicester, UK.  Her research experience spans a range of academic disciplines including health economics, health services research and medical statistics, and most excitingly, the interface and integration of all three.  Nicola joined the Biostatistics group at Leicester in 2000 and since then, her research has focused on the development and application of methods for evidence synthesis and economic decision modelling to inform health technology appraisals.  This research has led to collaborations with renowned experts in the area both nationally and internationally, leading to numerous research grants and the development of specialist courses delivered worldwide.  The paper, on which the 2012 ISPOR Award for Value in Health Paper of the Year was awarded, was funded by an MRC methodology grant and is an example of the collaborative research Nicola is currently undertaking.


Susan C. Griffin, PhD

Susan C. Griffin, PhD, is a Senior Research Fellow based in the Team for Economic Evaluation and Health Technology Assessment. She joined the Centre for Health Economics in 2002 and holds a BSc in Economics, an MSc in Health Economics and a PhD on ‘Dealing with uncertainty in the economic evaluation of health care technologies.’  In 2008, Dr. Griffin became a Research Council UK Academic Fellow in Health Economics and Public Health.  She also helped to develop a short course on the use of regression analysis for health economic evaluation.  Dr. Griffin currently serves as a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee. Dr. Griffin has contributed to numerous technology appraisals for NICE in her role as a member of one of the independent academic groups contracted to conduct assessments and evidence reviews for NICE.  In addition, Dr. Griffin has worked on economic evaluations in the fields of cardiovascular disease, HIV/AIDS, cancer and mental health.  Her research interests include the use of decision-analytic models in cost-effectiveness analysis and the use of evidence synthesis techniques and value of information analysis.  Dr. Griffin is currently researching the application of methods for economic evaluation in the field of public health.


Niteesh K. Choudhry, MD, PhD

Niteesh K. Choudhry, MD, PhD, is an internist and health services researcher whose work focuses on the clinical and economic consequences of evidence-based therapies for the management of common chronic conditions.  He is particularly interested in the design and evaluation of novel strategies to overcome barriers to treatment initiation and long-term medication adherence.  His work employs a broad range of methods including randomized policy evaluations, cost-effectiveness modeling, claims analyses, and surveys.  Dr. Choudhry is an Associate Professor at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital.  He received his MD and completed his residency training in Internal Medicine at the University of Toronto, did his PhD in Health Policy at Harvard University and was a Fellow in Pharmaceutical Policy Research at Harvard Medical School.  He practices inpatient general internal/hospital medicine and is actively involved in resident education.


Joanne LaFleur, PharmD, MSPH

Joanne LaFleur, PharmD, MSPH, is Assistant Professor in the Department of Pharmacotherapy within the University of Utah College of pharmacy. She has a joint appointment as a researcher in the Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) center, where she focuses on applying the tools of health economics, biomedical informatics, and pharmacoepidemiology to outcomes research. She received her PharmD degree from the University of Utah in 2003 and went on to complete a Fellowship in Pharmacoeconomics and Outcomes Research and a Master’s degree in Public Health in 2005, both at the University of Utah. She spent 4 years as faculty on the research track, and recently changed tracks to join the tenure track faculty. The focus of her CDA, entitled “Knowledge engineering for decision support in osteoporosis,” is on the development of clinical decision support tools for osteoporotic fracture prevention.